Last reviewed · How we verify

NCT04708626

Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden

Completed Last updated 9 November 2022
What this trial tests

trial testing Description and analysis in Autoimmune Encephalitis in 110 participants. Completed in 1 August 2022.

Timeline
1 October 2019
Primary endpoint
1 August 2022
1 August 2022

Quick facts

Lead sponsorUppsala University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment110
Start date1 October 2019
Primary completion1 August 2022
Estimated completion1 August 2022
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Uppsala University

Who can join

Eligibility, any sex, with Autoimmune Encephalitis or Paraneoplastic Neurological Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autoimmune encephalitis and paraneoplastic neurological syndromes are rare diseases caused by an abnormal immune response toward the nervous system. This can lead to life-threatening symptoms, but is in many cases treatable if a swift and correct diagnosis is made. Antibodies targeting neuronal proteins (i.e. "neuronal antibodies") can be detected in serum or cerebrospinal fluid (CSF) in about half of the patients suffering from these conditions. Although an important part of the diagnostical process of these conditions, diagnosis cannot be made only based on a positive antibody test, but the clinical findings have to be compatible as well. As these conditions are so rare, clinicians might struggle to interpret antibody test results. In this study the investigators aim to estimate the incidence rate of autoimmune encephalitides and paraneoplastic neurological syndromes in the Uppsala-Örebro health care region in Sweden between the years 2015 and 2019. Medical records from patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or CSF will be studied to obtain clinical, laboratory and radiological data. This data will be used to ascertain if diagnostic criteria are fulfilled as well as to describe clinical characteristics and identifying possible comorbidities.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Medical Applications of Molecular Biotechnologies in the Context of Hashimoto's Thyroiditis.
    Trovato M, Valenti A. · · 2023 · cited 1× · PMID 37371008 · DOI 10.3390/diagnostics13122114

Verify or expand the search:

Other trials of Description and analysis

Trials testing the same drug.

Other recruiting trials for Autoimmune Encephalitis

Currently open trials in the same condition.

Other Uppsala University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04708626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing